Why is Concord Biotech falling/rising?

As of 04-Sep, Concord Biotech Ltd's stock price is currently at 1,666.50, reflecting a decrease of 14.15 points or 0.84%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 1.57% during this period. Additionally, the stock's performance over the past month shows a decline of 1.99%, while year-to-date it has dropped significantly by 24.59%. Despite a high management efficiency indicated by a return on equity (ROE) of 19.76% and a low debt-to-equity ratio, the company is facing challenges with poor long-term growth, as evidenced by a substantial drop in profit after tax and net sales in the most recent quarter. The stock is also trading at a premium compared to its peers, which, combined with a high price-to-book value and a PEG ratio of 3.6, suggests that it may be overvalued.
In the broader market context, Concord Biotech's short-term performance has been lackluster compared to the benchmark, with the stock underperforming the Sensex by 0.69% today. While the Sensex has gained 0.80% over the past week, Concord Biotech has only managed a slight increase of 0.03%. Furthermore, the decline in institutional investor participation, with a decrease in their stake by 0.54%, indicates a lack of confidence from more experienced investors, which could further contribute to the stock's downward trend. Overall, the combination of poor recent financial performance, high valuation metrics, and declining institutional interest paints a challenging picture for Concord Biotech in the current market environment.